SpectraScience, Inc. Names Hughes Wielemans as Director of Business Development in Europe

SAN DIEGO, CA--(Marketwire - January 30, 2012) - SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego based medical device company, today announced it has named Hughes Wielemans as Director of Business Development, Europe, effective February 1.

Mr. Wielemans has more than 20 years of commercial experience in the European medical device industry, has built distributor networks and managed new product introductions throughout the European Union.

“Hughes has extensive knowledge of European medical device markets, and a successful track record of building customer bases and growing sales,” said Michael Oliver, SpectraScience’s Chief Executive Officer. “His contacts and experience in our target markets will enable us to accelerate the introduction of our WavSTAT4 Optical Biopsy System.”

Most recently Mr. Wielemans was Director of Sales and Marketing, Europe, for USGI Medical Ltd., where he developed a market entry strategy and business plan for major EU markets, and managed commercial and distribution agreements. Earlier he served as Director of Sales and Marketing for Covidien in Belgium, where he managed a team of 65 sales professionals; and as European Product Director for Tyco Healthcare covering the EMEA area.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding SpectraScience’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended December 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. SpectraScience disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.